Announcements Trials
Browse Landscape

Phase

Phase 2 10Phase 1/2 4Phase 3 2Phase NA 1Phase 1 1

Status

Recruiting 16Active not recruiting 10Completed 9Terminated 4Unknown 2Not yet recruiting 2Withdrawn 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2

Conditions

Multiple Myeloma 2Recurrence 1

Interventions

Cisplatin 129Radiotherapy 94Carboplatin 82Fluorouracil 77Paclitaxel 76Cyclophosphamide 76Gemcitabine 71Capecitabine 66Docetaxel 64Doxorubicin 59Oxaliplatin 57Etoposide 57Leucovorin 48Vincristine 46Chemotherapy, Adjuvant 42Cytarabine 38Dexamethasone 35Drug Therapy 33Bevacizumab 30Epirubicin 29Pemetrexed 27Neoadjuvant Therapy 26Irinotecan 25Tamoxifen 24Prednisone 23Methotrexate 21Rituximab 19Vinorelbine 18Radiotherapy, Intensity-Modulated 18Peripheral Blood Stem Cell Transplantation 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Unknown × pomalidomide × Clear all
NCT05236621 2022-02-11

A Study of the Efficacy and Safety of Pomalidomide Capsules Combined With Low-Dose Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma

Qilu Pharmaceutical Co., Ltd.

Phase 3 Unknown
85 enrolled
Plasma cell

Multiple Myeloma, Recurrence

NCT02916420 2016-11-02

Efficacy and Safety of Pomalidomide in Combination With Low-dose Dexamethasone in Chinese Patients With Relapsed and Refractory Multiple Myeloma

Jiangsu Simcere Pharmaceutical Co., Ltd.

Phase 3 Unknown
73 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡